| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $40.2M | -34.6% |
| SG&A Expense | $25.0M | -39.9% |
| Operating Income | -$70.4M | +35.0% |
| Net Income | -$64.8M | +36.5% |
| EPS (Basic) | -$1.07 | +42.5% |
| EPS (Diluted) | -$1.07 | +42.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $37.6M | +73.1% |
| Current Assets | $78.8M | -33.2% |
| Total Assets | $102.4M | -32.0% |
| Current Liabilities | $19.4M | +18.5% |
| Total Liabilities | $41.2M | +4.8% |
| Stockholders' Equity | $61.3M | -45.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$48.0M | +38.7% |
| Investing Cash Flow | $54.9M | -15.8% |
| Financing Cash Flow | $8.9M | +6473.3% |